Screening and surveillance for Barrett's esophagus: Current issues and future directions

Current Opinion in Gastroenterology

Volumn 28, Issue 4, 2012, Pages 377-381

  Choi, Sung E ^a   Hur, Chin ^a,b,c  

^a Institute for Technology Assessment   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Barrett's esophagus; cost effectiveness; esophageal adenocarcinoma; surveillance

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ANEUPLOIDY; AUTOFLUORESCENCE IMAGING; BARRETT ESOPHAGUS; CANCER RISK; CARDIA; CONFOCAL LASER MICROSCOPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SURVEILLANCE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS DYSPLASIA; GASTROESOPHAGEAL REFLUX; HETEROZYGOSITY LOSS; HUMAN; INTESTINE METAPLASIA; META ANALYSIS (TOPIC); NARROW BAND IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW (TOPIC); WHITE LIGHT ENDOSCOPY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84862297623     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328353d58e     Document Type: Review

References (35)

1. American Cancer Society ACS. Cancer Facts & Figures 2012. Atlanta: American Cancer Society, 2012. (http://www.cancer.org/acs/groups/con tent/@epidemiologysurveilance/documents/document/acspc-031941.pdf)
2. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: A population-based study with temporal trends. Am J Gastroenterol 2009; 104:1356-1362.
3. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.AmJ Gastroenterol 2008; 103:788-797.
4. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140:e18-e52.
5. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333-338.
6. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-Analysis. Am J Epidemiol 2008; 168:237-249.
7. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053.
8. Somerville M, Garside R, Pitt M, Stein K. Surveillance of Barrett's oesophagus: Is it worthwhile? Eur J Cancer 2008; 44:588-599.
9. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: A population-based study. Gastroenterology 2002; 122:633-640.
10. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-1895.
11. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in nondysplastic Barrett's oesophagus: A meta-Analysis. Gut 2011. [Epub ahead of print]
12. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: Results from a large population-based study. J Natl Cancer Inst 2011; 103:1049-1057.
13. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365:1375-1383.
14. Das A, Wells C, Kim HJ, et al. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus. Endoscopy 2009; 41:400-408.
15. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003; 138:176-186.
16. Inadomi JM, Somsouk M, Madanick RD, et al. A cost-utility analysis of ablative, therapy for Barrett's esophagus. Gastroenterology 2009; 136:2101-2114.
17. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther 2002; 16:41-50.
18. Hirst NG, Gordon LG, Whiteman DC, et al. Is endoscopic surveillance for nondysplastic Barrett's esophagus cost-effective? J Gastroenterol Hepatol 2011; 26:247-254.
19. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89:670-680; Epub 1994/05/01.
20. Egger K, Werner M, Meining A, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut 2003; 52:18-23.
21. Wolfsen HC, Crook JE, Krishna M, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's Esophagus. Gastroenterology 2008; 135:24-31.
22. Curvers WL, Van den Broek FJ, Reitsma JB, et al. Systematic review of narrowband imaging for the detection and differentiation of abnormalities in the esophagus and stomach (with video). Gastrointest Endosc 2009; 69:307-317.
23. Curvers WL, Herrero LA, Wallace MB, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 2010; 139:1106-1114.
24. Sharma P, Meining AR, Coron E, et al. Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: Final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2011; 74:465-472.
25. Gaddam S, Mathur SC, Singh M, et al. Novel probe-based confocal laser endomicroscopy criteria and interobserver agreement for the detection of dysplasia in Barrett's esophagus. Am J Gastroenterol 2011; 106:1961-1969.
26. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360:2277-2288.
27. Blount PL, Ramel S, Raskind WH, et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991; 51:5482-5486.
28. Cawley HM, Meltzer SJ, De Benedetti VM, et al. Antip53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998; 115:19-27.
29. Barrett MT, Galipeau PC, Sanchez CA, et al. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996; 12:1873-1878.
30. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999; 22:106-109.
31. Dolan K, Garde J, Gosney J, et al. Allelotype analysis of oesophageal adenocarcinoma: Loss of heterozygosity occurs at multiple sites. Br J Cancer 1998; 78:950-957.
32. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107:1012-1018.
33. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96:2839-2848.
34. Sato F, Jin Z, Schulmann K, et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PloS One 2008; 3:e1890.
35. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009; 69:4112-4115.